Clinical Trial Update: P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for P-BCMA-101 Tscm CAR-T cells in multiple myeloma; trial status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• P-BCMA-101 Tscm CAR-T cells (P-BCMA-101 Tscm CAR-T cells)

Snippet

Sponsor: Poseida Therapeutics, Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-06-22